Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schirra, J
Right arrow Articles by Katschinski, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schirra, J
Right arrow Articles by Katschinski, M
Gut 2002;50:341-348
© 2002 by Gut


MOTILITY AND VISCERAL SENSATION

Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans

J Schirra1, U Wank1, R Arnold1, B Göke2, M Katschinski1

1 Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
2 Department of Gastroenterology, Ludwig-Maximilians University, Munich, Germany

Correspondence to:
Correspondence to:
Professor M Katschinski, Department of Gastroenterology, Baldingerstr, 35033 Marburg, Germany;
katschin{at}post.med.uni-marburg.de


ABSTRACT
Background: Glucagon-like peptide-1(7–36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility.

Aims: To assess the effects of synthetic GLP-1 on fundus tone and volume waves, gastric compliance, and perception of gastric distension.

Subjects: Eleven healthy male volunteers.

Methods: Background infusions were saline, or GLP-1 at 0.3 or 0.9 pmol/ kg/min on separate days in random order. Interdigestive fundus motility was recorded by barostat (maximum capacity of intragastric bag 1200 ml) during basal and peptide periods of 60 minutes each. Thereafter stepwise isobaric distensions were performed with ongoing peptide infusion, and gastric sensation was scored.

Results: Low and high loads of GLP-1 induced physiological and supraphysiological plasma immunoreactivities, respectively. GLP-1 dose dependently diminished fundus tone (162.9 (15.0) and 259.5 (17.2) v 121.1 (6.0) ml with saline; p<0.0001). It greatly reduced volume waves and total volume displaced by these events (p<0.0001). Gastric compliance derived from isobaric distension rose in a dose related manner (42.6 (5.5) and 63.6 (7.7) v 27.0 (3.5) ml/mm Hg; p=0.0004) with a concomitant reduction of the pressure at half maximum bag volume (6.4 (0.4) and 5.5 (0.4) v 7.2 (0.1) mm Hg; p<0.0001). GLP-1 did not change perception of isobaric distension but reduced the perception score related to corresponding bag volume (p<0.0001).

Conclusions: GLP-1 is a candidate physiological inhibitory regulator of fundus motility. It allows the stomach to afford a larger volume without increase in sensation.


Keywords: barostat; gastric compliance; gastric tone; isobaric distension; volume waves

Abbreviations: CCK, cholecystokinin; GLP-1, glucagon-like peptide-1(7-36)amide; IR, immunoreactive; MDP, minimal distending pressure; PP, pancreatic polypeptide




This article has been cited by other articles:


Home page
DiabetesHome page
A. Vella, G. Bock, P. D. Giesler, D. B. Burton, D. B. Serra, M. L. Saylan, B. E. Dunning, J. E. Foley, R. A. Rizza, and M. Camilleri
Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes
Diabetes, May 1, 2007; 56(5): 1475 - 1480.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen
Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not
Diabetes, January 1, 2007; 56(1): 8 - 15.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. J. Little, A. N. Pilichiewicz, A. Russo, L. Phillips, K. L. Jones, M. A. Nauck, J. Wishart, M. Horowitz, and C. Feinle-Bisset
Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1916 - 1923.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
Gut, February 1, 2006; 55(2): 243 - 251.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
B D J van den Elzen, R J Bennink, R E Wieringa, G N J Tytgat, and G E E Boeckxstaens
Fundic accommodation assessed by SPECT scanning: comparison with the gastric barostat
Gut, November 1, 2003; 52(11): 1548 - 1554.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 BMJ Publishing Group Ltd & British Society of Gastroenterology